# US 2022/0031650 A1 · Stimulation of an immune response by cationic lipids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031650 A1
- Document ID: US20220031650A1
- Status: Published application
- Kind: A1
- Application number: 17/383,104
- Filed: 2021-07-22
- Published: 2022-02-03
- Earliest claimed: 2007-03-22
- Assignees: PDS Biotechnology Corporation
- Applicants: PDS Biotechnology Corporation
- Inventors: Weihsu Chen; Weili Yan; Kenya Johnson; Gregory Conn; Frank Bedu-Addo; Leaf Huang
- Web page: https://patentgrep.com/patent/US20220031650A1

## CPC

- A61K 31/231: having one or two double bonds
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 219/06: having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

## Claims

### Claim 1

A method of treating a coronavirus infection in a mammal, the method comprising administering at least one cationic lipid together with at least one coronavirus-associated antigen, wherein the cationic lipid is administered to the mammal in an amount sufficient to activate the MAP kinase signaling pathway to elicit an immunostimulatory adjuvant effect, wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol, and wherein the mammal dose of cationic lipid is determined from the mouse dose.

### Claim 2 (depends on 1)

The method of claim 1 wherein the cationic lipid is a nonsteroidal cationic lipid comprising at least one fatty acid or alkyl chain.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1 wherein the cationic lipid is DOTAP.

### Claim 5 (depends on 1)

The method of claim 1 wherein the immunostimulatory adjuvant effect results in the attenuation or curing of the coronavirus infection.

### Claim 6 (depends on 1)

The method of claim 1 wherein the antigen is modified to increase its hydrophobicity, wherein the antigen is modified via conjugation to a lipid chain or via conjugation to one or more hydrophobic amino acids.

### Claim 7 (depends on 6)

The method of claim 6 wherein the coronavirus-associated antigen is a lipidated antigen.

### Claim 8 (depends on 7)

The method of claim 7 wherein the coronavirus-associated antigen is lipidated with palmitic acid.

### Claim 9 (depends on 8)

The method of claim 8 wherein the palmitic acid is linked to the coronavirus-associated antigen via a spacer, wherein the spacer is an amino acid sequence of K-S-S.

### Claim 10

A method of reducing the regulatory T-cell population in a mammal in need thereof, the method comprising administering to the mammal at least one cationic lipid and at least one coronavirus-associated antigen, wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol, and wherein the mammal dose of cationic lipid is determined from the mouse dose.

### Claim 11 (depends on 10)

The method of claim 10 wherein the cationic lipid is a nonsteroidal cationic lipid comprising at least one fatty acid or alkyl chain.

### Claim 12 (depends on 10)

The method of claim 10 wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.

### Claim 13 (depends on 10)

The method of claim 10 wherein the cationic lipid is DOTAP.

### Claim 14

A method of using a cationic lipid to elicit an immunostimulatory adjuvant effect in an immune system of a mammal, wherein the cationic lipid is administered with at least one coronavirus-associated antigen to the mammal in an amount sufficient to activate the MAP kinase signaling pathway to elicit the immunostimulatory adjuvant effect, wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol, and wherein the mammal dose of cationic lipid is determined from the mouse dose.

### Claim 15 (depends on 14)

The method of claim 14 wherein the cationic lipid is a nonsteroidal cationic lipid comprising at least one fatty acid or alkyl chain.

### Claim 16 (depends on 14)

The method of claim 14 wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.

### Claim 17 (depends on 14)

The method of claim 14 wherein the cationic lipid is DOTAP.

### Claim 18 (depends on 1)

The method of claim 1 wherein the amount of cationic lipid is between about 30 nmol and about 300 nmol.

### Claim 19 (depends on 10)

The method of claim 10 wherein the amount of cationic lipid is between about 30 nmol and about 300 nmol.

### Claim 20 (depends on 14)

The method of claim 14 wherein the amount of cationic lipid is between about 30 nmol and about 300 nmol.

### Claim 21

A method of inducing an antibody response against an coronavirus-associated antigen in a mammal, the method comprising administering at least one cationic lipid together with at least one coronavirus-associated antigen, wherein the cationic lipid is administered to the mammal in an amount sufficient to induce the antibody response in response against the antigen, wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol, and wherein the mammal dose of cationic lipid is determined from the mouse dose.

### Claim 22 (depends on 21)

The method of claim 21 wherein the cationic lipid is a nonsteroidal cationic lipid comprising at least one fatty acid or alkyl chain.

### Claim 23 (depends on 21)

The method of claim 21 wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.

### Claim 24 (depends on 21)

The method of claim 21 wherein the cationic lipid is DOTAP.

### Claim 25 (depends on 21)

The method of claim 21 wherein the coronavirus-associated antigen is modified to increase its hydrophobicity, wherein the antigen is modified via conjugation to a lipid chain or via conjugation to one or more hydrophobic amino acids.

### Claim 26 (depends on 25)

The method of claim 25 wherein the coronavirus-associated antigen is a lipidated antigen, and wherein the lipidated antigen is lipidated with palmitic acid.

### Claim 27 (depends on 26)

The method of claim 26 wherein the palmitic acid is linked to the antigen via a spacer, wherein the spacer is an amino acid sequence of K-S-S.

### Claim 28 (depends on 21)

The method of claim 21 wherein the amount of cationic lipid is between about 30 nmol and about 300 nmol.

### Claim 29 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 30 (depends on 1)

The method of claim 1, wherein the mammal is a non-human.

### Claim 31 (depends on 1)

The method of claim 1, wherein the mouse dose of cationic lipid is between 0.05 nmol per microliter (μL) to about 3 nmol per μL.

### Claim 32 (depends on 1)

The method of claim 1, wherein the mouse dose of cationic lipid is between 0.05 mg per milliliter (mL) to about 2 mg per mL.

### Claim 33 (depends on 10)

The method of claim 10, wherein the mammal is a human.

### Claim 34 (depends on 10)

The method of claim 10, wherein the mammal is a non-human.

### Claim 35 (depends on 10)

The method of claim 10, wherein the mouse dose of cationic lipid is between 0.05 nmol per microliter (μL) to about 3 nmol per μL.

### Claim 36 (depends on 10)

The method of claim 10, wherein the mouse dose of cationic lipid is between 0.05 mg per milliliter (mL) to about 2 mg per mL.

### Claim 37 (depends on 14)

The method of claim 14, wherein the mammal is a human.

### Claim 38 (depends on 14)

The method of claim 14, wherein the mammal is a non-human.

### Claim 39 (depends on 14)

The method of claim 14, wherein the mouse dose of cationic lipid is between 0.05 nmol per microliter (μL) to about 3 nmol per μL.

### Claim 40 (depends on 14)

The method of claim 14, wherein the mouse dose of cationic lipid is between 0.05 mg per milliliter (mL) to about 2 mg per mL.

### Claim 41 (depends on 21)

The method of claim 21, wherein the mammal is a human.

### Claim 42 (depends on 21)

The method of claim 21, wherein the mammal is a non-human.

### Claim 43 (depends on 21)

The method of claim 21, wherein the mouse dose of cationic lipid is between 0.05 nmol per microliter (μL) to about 3 nmol per μL.

### Claim 44 (depends on 21)

The method of claim 21, wherein the mouse dose of cationic lipid is between 0.05 mg per milliliter (mL) to about 2 mg per mL.
